TDSC Announced Today The Receipt Of Its Releases To Begin Its Pivotal Phase Of Clinical Trials

Transdermal Delivery Solutions, a leader in the development of spray-on drug delivery systems, announced today they are entering the pivotal phase of clinical trials. The British National Health Service (NHS) Ethics filings (IRAS) and approval of Clinical Trial Applications (CTAs) for TDSC’s Investigational Medical Product Dossier on Hormone Replacement Technologies’ Testagen® HypoSpray® were filed in November, 2015.

Source:
www.businesswire.com/news/home/20160418006761/en/Transdermal-Delivery-Solutions-Announces-Regulatory-Approval-Clinical